Arbutus CEO Michael McElhaugh discussed trial results showing that a combination of imdusiran, an RNAi therapeutic, and pegylated interferon alfa-2α can achieve a functional cure in chronic hepatitis B patients.
Michael J McElhaugh
Advertisement
Interim President and CEO and Director of Arbutus Biopharma.
Articles by Michael J McElhaugh
Advertisement
Latest Updated Articles
Imdusiran for Chronic Hepatitis B Achieves Functional Cure in 50% of PatientsPublished: November 18th 2024 | Updated:
Advertisement
Advertisement
